Kornimate/medical-research-clean huggingface dataset:
cardiac magnetic resonance monitoring of immune checkpoint inhibitor-related cardiotoxicity

Conditions: Immune Checkpoint Inhibitors, Cardiotoxicity

Summary: this study is a prospective cohort clinical research that analyzes the changes in cmr parameters before and after immune checkpoint inhibitors (icis) therapy in patients with gynecologic malignancies. it also evaluates the value of cmr parameters in predicting long-term outcomes. the baseline assessment will be conducted prior to icis treatment, followed by multiple assessments during the medication process including within one week prior to cycle 3 , within the week prior to cycle 5 , 1 year after the first dose, and 2 years after the first dose. assessment will also be conducted after discontinuation of icis medication. the assessment includes clinical assessment, cmr imaging, echocardiography, serum cardiac injury biomarkers, etc. cancer therapy-related cardiac dysfunction (ctrcd), survival, and major adverse cardiac events (mace) will be followed up.


Eligibility criteria:
inclusion criteria: * 1. female patients aged 18 to 75 years, diagnosed with gynecological malignancies through histology or cytology. * 2. patients who are preparing for monotherapy or combination therapy with icis. * 3. voluntary signing of informed consent form. * 4. eastern cooperative oncology group (ecog) performance status of 0 or 1. * 5. expected survival of at least 6 months. exclusion criteria: * 1. previously received icis treatment. * 2. with allergies or contraindications to icis. * 3. confirmed to be brain metastasis. * 4. patients who have major surgery within 4 weeks prior to or following the screening period. * 5. patients who have received systemic corticosteroids (at a dose equivalent to \>10 mg prednisone per day) or other immunosuppressive medications within 14 days prior to enrollment or during the study period; however, the following situations are allowed for inclusion: 1. the use of topical or inhaled corticosteroids is permitted; 2. short-term (≤7 days) use of corticosteroids for prevention or treatment of non-autoimmune diseases is allowed. * 6. left ventricular ejection fraction (lvef) ≤50%, or new york heart association functional classification (nyha) ≥iii. * 7. coronary heart disease, cardiomyopathy, congenital heart disease, valvular heart disease and pericardial diseases with confirmed diagnosis. * 8. lack of autonomous capacity, or a documented history of mental disease. * 9. mri contraindications: pacemakers, neurostimulators, artificial metal heart valves, arterial aneurysm clips, intraocular metallic foreign bodies, inner ear implants, metal prostheses, metal limbs, metal joints, and any other metallic implants or foreign objects; severe hyperthermia patients; claustrophobia; severe respiratory conditions that prevent breath-holding.
systems biology approach to cognitive impairment after sepsis

Conditions: Sepsis; Cognitive Impairment

Summary: this study will use systems biology techniques, especially rna-seq, to understand cognitive impairment after sepsis requiring an intensive care unit (icu) admission.


Eligibility criteria:
inclusion criteria - either sepsis or septic shock a. sepsis: presence of 1. suspected or confirmed infection and 2. organ dysfunction as defined by a sofa \>= 2 above baseline (if no baseline data available, sofa assumed to be 0) or b. septic shock: after intravenous infusion of 20ml/kg crystalloid or equivalent, presence of 1. suspected or confirmed infection and 2. lactate \> 2 mmol/l and 3. receiving vasopressors enrollment within 48 hours of icu admission. must live within 200 miles of intermountain medical center subject is at least 18 years of age or older must speak english exclusion criteria: * onset of sepsis or septic shock \>24 hours after hospital admission * patients transferred from another hospital except for directly from an emergency room * patients transferred to the icu \>48 hours after admission to intermountain medical center (must have been admitted with diagnosis of sepsis) * prior traumatic brain injury, stroke, or intracranial hemorrhage * dnr/dni order before study enrollment * primary diagnosis of stroke or intracranial hemorrhage * known preexisting dementia or substantial cognitive impairment of any cause (established from both chart review, report and/or score ≥3 on iq code screening. * prior cardiac surgery (coronary artery bypass grafting or surgical valve replacement or repair) * known schizophrenia or other psychotic thought disorder * known pregnancy * primary diagnosis of drug overdose * attending physician deems aggressive care unsuitable * enrolled in another study if that study involves drug interventions * not expected to survive 48 hours * has a terminal condition independent of the acute illness that is expected to lead to death within 6 months
comparison of liver and renal function after transarterial chemoembolization for primary hepatocellular carcinoma with iso-osmolar contrast media and low osmolar contrast media

Conditions: Primary Hepatocellular Carcinoma

Summary: primary hepatocellular carcinoma (phc) is one of the most common malignant tumors in the world. in men is the fifth most frequently diagnosed cancer worldwide but the second most frequent cause of cancer death. in women, it is the seventh most commonly diagnosed cancer and the sixth leading cause of cancer death. an estimated 748,300 new liver cancer cases and 695,900 cancer deaths occurred worldwide in 2008. half of these cases and deaths were estimated to occur in china. surgical resection and liver transplantation can be curative treatment options, but less than 20% of phc patients are candidates for surgery. the prognosis of patients with unresectable phc is poor; if left untreated, the median survival is less than 6 months. since transarterial chemoembolization (tace) was introduced as a palliative treatment in patients with unresectable hcc, it has become one of the most common forms of interventional therapy. however, the possibility of treatment-related complication may offset the survival benefit, especially by the worsening of liver functions.tace increases several parameters of hepatic cytolysis and decreases the metabolic activity of the liver. such a deterioration of liver function due to ischemia following tace may result in liver failure, or even death. tace also may have an adverse effect on the kidney. radiographic contrast medium is used to obtain the hepatogram before tace. it has been shown that the use of contrast medium increases the risk of renal failure, especially the low-osmolar contrast media. the aim of this trials was to compare the change of liver and renal function after tace for hcc of iso-osmolar contrast media with that of low-osmolar contrast media.

this was a prospective, randomized, single centre, single-blind study. patients were randomized (1:1) to use low-osmolar contrast media or iso-osmolar contrast media for tace. on the morning of 2th and 5th days after tace, a hematologic check was performed, the hematologic check including serum creatinine, blood urea nitrogen, direct bilirubin, indirect bilirubin, alanine aminotransferase, aspartate aminotransferase, γ-glutamyltransferase, lactate dehydrogenase, alkaline phosphatase, cholinesterase. then, comparing them with the data before tace.

Eligibility criteria:
inclusion criteria: * 18-75 years; * phc that could not be treated with surgery; * patients with clear consciousness，cooperation; * informed consent: authorization and signature. exclusion criteria: * preexisting dialysis; * known hypersensitivity to the contrast media; * complete portal vein thrombosis (main trunk or both branches); * with severe cardiovascular or renal disease; * extensive arteriovenous shunting; * insufficient function of the remaining liver (child-pugh class c).

Keywords: primary hepatocellular carcinoma(hcc) transarterial chemoembolization (tace) liver function renal function
potential drug interactions with bisoprolol in egyptian patients with acs

Conditions: Acute Coronary Syndrome

Summary: acute coronary syndrome (acs) is any group of clinical symptoms compatible with acute myocardial ischemia and includes unstable angina (ua), non-st-segment elevation myocardial infarction (nstemi), and st-segment elevation myocardial infarction (stemi). (1). in egypt, the overall prevalence of coronary heart disease (chd) is 8.3 % (2). in addition, chd in egypt is the principal cause of death, responsible for 21.73% of total mortality (2). beta-blockers have shown to reduce the short-term risk of a reinfarction and the long-term risk of all-cause mortality and cardiovascular mortality (3). beta blockers are used within 24 hours of acs and given as long-term therapy after discharge (4). the most frequently used drug in egypt is bisoprolol. in patients with myocardial infarction undergoing primary percutaneous coronary intervention, early intravenous betablocker before reperfusion reduced infarct size and increased left ventricular ejection fraction (4).drug interactions are common in acs patients due to polypharmacy and comorbidities.(5) there are limited studies investigating drug interactions with bisoprolol in acute coronary syndrome patients. the proposed research in this application will investigate potential drug interactions with bisoprolol in patients with acute coronary syndrome.

1. ethical committee approval will be obtained from ethics committee of faculty of pharmacy, damanhour university. 2. all participants should agree to take part in this clinical study and will provide informed consent. 3. over 100 patients diagnosed with acute coronary syndrome for whom bisoprolol therapy is prescribed , will be recruited from alexandria university hospital. 4. blood samples for plasma concentration measurements of bisoprolol will be drawn at steady-state peak levels after 2-4 hours of administration of bisoprolol. 6. heart rate and blood pressure of the patients will be measured to assess the clinical effect of bisoprolol.

Eligibility criteria:
inclusion criteria: 1. patients admitted with chest pain suspected to have acs (acute coronary syndrome). 2. both with st elevation (stemi) and without st elevation (n-stemi ) and unstable angina. 3. indicated to bisoprolol therapy exclusion criteria: patients with contraindications to bisoprolol therapy:
clinical spectrum and outcome of poisoning in children admitted to the pediatric emergency and intensive care units at sohag university hospital

Conditions: Acute Poisoning

Summary: acute poisoning is a major health problem that leads to emergent hospital admission.it has become the main factor that harms children and leads to disability and death of children. also, it is still a serious issue in developing countries where it represents a common cause of emergency department presentation and admission. acute poisoning can be divided into two categories (accidental and intentional),accidental poisoning is common in children under five years, whereas intentional poisoning is more common in adolescents, who estimated that, in 2016, accidental poisoning caused 106,683 deaths and the loss of 6.3 million years of healthy life. a study in romania showed that intentional poisoning is the most common cause of poisoning among teenagers. females are more vulnerable to suicidal or intentional poisoning than males. medications, alcohol, and substance abuse are common poisoning agents among teenagers , another study at tertiary indian hospital, pesticides, pharmaceutical drugs, and household products were the most common types of acute poisoning. pesticides were reported as a cause of intentional and accidental poisoning. in agricultural areas, people were poisoned accidentally by pesticides that may be used for suicidal attempts because of their availability. pharmaceutical drugs are also used for intentional poisoning due to the availability of street drugs and over-the-counter medications. accidental poisoning by household products were observed in children and the most common products are hydrocarbon and naphthalene in egypt acute poisoning represents a significant proportion of emergency visits of children and young people. this labors a burden on healthcare, society and economy and thus, it drain-s resources and multiplies workload . in fact, it is a preventable cause of morbidity and mortality. children poisoning is a result of multiple risk factors including social, demographic, and industrial factors. insufficient public awareness, easy accessibility to poison, negligence of caregivers, technological and industrial advances and even the nature of the environment are of the main causes.


Eligibility criteria:
inclusion criteria: * all patients admitted to pediatric emergency and intensive care units with claim or suspected to have acute poisoning aged from 1 month up to 18 years old. exclusion criteria: * children with chronic poisoning * no clear history or clinical picture of definite toxic poison * incomplete clinical data
behavior analytic support of needle-related hospital visits for autistic patients

Conditions: Autism Spectrum Disorder

Summary: the purpose of this study is to evaluate the effectiveness of the behavior analytic intervention in reducing the number of challenging behaviors exhibited by patients with autism spectrum disorder (asd) while increasing compliance with needle-related simulations and procedures. a second purpose is to assess the social validity of this study as evidenced by patient and/or caregiver acceptability. the study wil take place at boston medical center (bmc). a single subject design (ssd) wil be utilized as it allows for detailed, individualized assessment of how interventions affect behavior over time in this type of behavior analytic research. by focusing on each participant as an individual and having each participant act as their own control, it demonstrates clear cause-and-effect relationships, showing how behavior changes with the introduction or withdrawal of an intervention. this method is flexible, enabling ongoing adjustments to treatments based on real-time data, making it particularly useful in personalized interventions and ensuring effectiveness for patients with unique needs such as those who would be eligible to enroll and participate in this study.


Eligibility criteria:
inclusion criteria: * caregivers of autistic patients who have been historically engaged in challenging behaviors during needle-related procedures at a boston medical center (bmc) * established bmc autistic patients (ages 3+) who have a history of engaging in challenging behaviors in the presence of needle-related medical stimuli. * bmc medical providers (i.e., phlebotomists, medical doctors, registered nurses, certified nursing assistants, registered dieticians, and medical assistants) who either: 1) order needle-related medical procedures for participants to be conducted during procedure visits and/or 2) are present to conduct the ordered procedure * english speaking participants exclusion criteria: * patients who are unable to visit bmc a minimum of 2 times per month * no history of challenging behaviors in medical appointments involving the presentation of needle(s) * patients and caregivers who do not speak english or are unable to utilize interpreter services to complete assessments and surveys

Keywords: behavior analytic research needle-related healthcare visits simulation visits differential reinforcement of alternative behavior (dra)
study of massage therapy within a brain tumor setting

Conditions: Brain Tumors

Summary: the purpose of this study is * to assess the feasibility and acceptability of massage therapyto examine the effects of massage therapy * to explore whether psychological outcomes are associated with changes in patient reported qol.

as a part of this study, we will provide massage therapy to brain tumor patients. our contribution here is expected to determine whether massage therapy is safe and helps to improve patient qol. this contribution is significant because it is expected to provide pilot data on effect sizes so that we may design an adequately powered study to develop massage therapy programs and interventions for patients with brain tumors. in addition to benefiting brain tumor patients, the information from this study may be applied to improving the qol of other cancer patients.

Eligibility criteria:
inclusion criteria: * patients with histological confirmed, newly diagnosed, post surgical who grade iii/iv malignant glioma (i.e., glioblastoma, anaplastic astrocytoma) being followed at the preston robert tisch brain tumor center (prt-btc) at duke university medical center (dumc) will be considered potential participants for this study. * additional eligibility criteria will be: 1. \> 18 years old 2. karnofsky performance score of \> 70 at onset of study 3. estimated life expectancy of \> 3 months 4. approval from attending oncologist 5. the ability to speak, read and write english 6. live within a 60 mile radius of the dcl 7. be identified as "stressed" by perceived stress scale (pss) score, \> 12.1 and 13.7 for men and women respectively, and 8) signed informed consent prior to initiation of study-related procedures. exclusion criteria: * n/a

Keywords: massage therapy in patients with brain tumors
study to evaluate the efficacy, safety, and tolerability of bms-986368, for the treatment of agitation in participants with alzheimer's disease

Conditions: Agitation; Alzheimer Disease

Summary: this is a study to evaluate the efficacy, safety, and tolerability of bms-986368, a faah/magl inhibitor, for the treatment of agitation in participants with alzheimer's disease.


Eligibility criteria:
inclusion criteria: * participants with a diagnosis of alzheimer's disease with biomarker confirmation meeting the 2024 revised criteria for diagnosis and staging of ad: alzheimer's association workgroup. * the diagnosis of agitation must meet the international psychogeriatric association (ipa) definition of agitation. * history of agitation with onset at least four weeks prior to screening * mmse-1 score \< 21 * npi-nh agitation/aggression sub-score ≥ 4. * stable living environment for at least 6 weeks prior to screening. participants are eligible if they are in nursing homes, assisted living facilities, or living at home and have an identified study partner (caregiver). * capable of self-locomotion (alone or with the aid of an assistive device); wheelchairs and other mobility aids are acceptable. exclusion criteria: * clinically significant delusions/hallucinations requiring hospitalization. * history of bipolar disorder, schizophrenia, or schizoaffective disorder. * history of major depressive episode with psychotic features during the 12 months prior to screening. * history of delirium within 30 days of screening. * other protocol-defined inclusion/exclusion criteria apply.
effects of alcohol on simulated driving

Conditions: Alcoholism

Summary: previous studies have shown that alcohol significantly impairs driving performance. acute alcohol administration also has a detrimental effect on secondary task performance during dual-tasks. the present study will investigate the effects of five different dosages of ethanol (0,0.2, 0,5, 0,8 and 1,0 % bac) on performance in a driving simulator. steering performance and brain activity will be recorded in both single- and dual-task conditions.


Eligibility criteria:
inclusion criteria: * he/she is aged between 21-50 * written informed consent * right-handed * normal static binocular acuity, corrected or uncorrected * normal hearing * social drinker (average of 7 to 21 alcoholic drinks per week) * possession of a drivers license * be considered as reliable and mentally capable of adhering to the protocol. exclusion criteria: * current drug use (positive urine drug screen on the presence of amphetamines (including mdma), barbiturates, cannabinoids, benzodiazepines, cocaine, and opiates) * positive urine pregnancy drug screen in women * use of psychoactive medication * positive alcohol breath test * prior enrolment in the same study * physical or mental illness * excessive alcohol use (\>21 alcoholic drinks per week) * excessive smoking (more than 10 cigarettes per day) * intake of caffeine-containing beverages over 5 glasses per day

Keywords: alcohol driving multitasking erp social drinkers
ex-vivo perfusion and ventilation of lungs recovered from non-heart-beating donors to assess transplant suitability

Conditions: Emphysema; Chronic Obstructive Pulmonary Disease (COPD); Cystic Fibrosis; Pulmonary Fibrosis; Bronchiectasis; Sarcoidosis; Pulmonary Hypertension; Alpha-1 Antitrypsin Deficiency

Summary: the purpose of this research study is to learn about the safety of transplanting lungs obtained from non-heart-beating donors (nhbds) that have been ventilated (attached to a breathing machine or ventilator to deliver oxygen) and perfused with a lung perfusion solution (steen solution™, made by vitrolife). this ventilation and perfusion will be done outside the body (ex-vivo) in a modified cardiopulmonary bypass circuit (the kind of device used routinely during most heart surgeries). the purpose of performing ex-vivo perfusion and ventilation is to learn how well the lungs work, and whether they are likely safe to transplant.


Eligibility criteria:
inclusion criteria: * a recipient must meet the following requirement to enroll into the study: * requires a single or bilateral lung transplant and is listed for transplant at unc or duke * male or female, 15 years of age or older. * subject or subject's representative provides a legally effective informed consent. * recipient does not have hiv, active hepatitis or is colonized with burkholderia cepacia. * potential subjects who have undergone previous lung transplants and meet all other inclusion criteria, are eligible for study participation. exclusion criteria: •recipient fails to meet standard of care requirements for lung transplant, or decides not to participate.

Keywords: lung transplant emphysema chronic obstructive pulmonary disease (copd) cystic fibrosis pulmonary fibrosis bronchiectasis sarcoidosis pulmonary hypertension alpha-1 antitrypsin deficiency
demonstrate the equivalence of ct-p10 to mabthera with respect to the pharmacokinetic profile in patients with rheumatoid arthritis

Conditions: Rheumatoid Arthritis

Summary: this randomized,controlled, multicenter, 2-arm, parallel-group, double-blind, prospective, phase 1 study is designed to demonstrate comparable pharmacokinetics in terms of auc0-last and cmax (after second infusion) between ct-p10 and mabthera in patients with active ra concomitantly treated with mtx during the core study period.


Eligibility criteria:
inclusion criteria: 1. patient has a diagnosis of ra according to the revised 1987 acr classification criteria (arnett et al 1987) for at least 6 months prior to randomization. 2. patient has active disease as defined by the presence of 6 or more swollen joints (of 66 assessed) and 6 or more tender joints (of 68 assessed), and serum crp ≥1.5 mg/dl or an esr ≥28 mm/hour. exclusion criteria: 1. patient is unresponsive or intolerable to more than 2 biologic agents. 2. patient has allergies or hypersensitivity to murine, chimeric, human, or humanized proteins. 3. patient has current or past history of chronic infection with hepatitis b, hepatitis c, or infection with human immunodeficiency virus (hiv)-1 or -2 or who has a positive result to the screening test for these infections.

Keywords: ra, biosimilar